prednisone has been researched along with Atherogenesis in 14 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The efficacy of immunosuppressive doses of oral prednisone to inhibit in-stent neointimal proliferation was compared with BMS and with a commercially available paclitaxel-eluting stent (Taxus) in a rabbit model of established atherosclerosis." | 7.74 | Effects of oral prednisone after stenting in a rabbit model of established atherosclerosis. ( Acampado, E; Crimins, J; Ferrero, V; Finn, AV; Joner, M; Kolodgie, FD; Nakazawa, G; Ribichini, F; Vassanelli, C; Virmani, R, 2007) |
| " The efficacy of immunosuppressive doses of oral prednisone to inhibit in-stent neointimal proliferation was compared with BMS and with a commercially available paclitaxel-eluting stent (Taxus) in a rabbit model of established atherosclerosis." | 3.74 | Effects of oral prednisone after stenting in a rabbit model of established atherosclerosis. ( Acampado, E; Crimins, J; Ferrero, V; Finn, AV; Joner, M; Kolodgie, FD; Nakazawa, G; Ribichini, F; Vassanelli, C; Virmani, R, 2007) |
| " No differences in adiponectin or CRP were found in relation to AGH or atherosclerosis; however, there was a positive correlation between adiponectin levels and prednisone dose (r=0." | 3.74 | Ghrelin, glucose homeostasis, and carotid intima media thickness in kidney transplantation. ( Alonso, N; Barluenga, E; Genís, BB; Granada, ML; Homs, M; Jiménez, JA; Lauzurica, R; Pastor, MC; Quintero, JC; Romero, R; Salinas, I; Sanmartí, A, 2007) |
| " However, adjusting for age, sex, and classic atherosclerosis risk factors, no significant correlation between carotid IMT and the routine laboratory markers of inflammation assessed at the time of disease diagnosis, disease duration, or cumulative prednisone dose was found." | 3.74 | Atherosclerosis in patients with biopsy-proven giant cell arteritis. ( Gonzalez-Gay, MA; Gonzalez-Juanatey, C; Llorca, J; Lopez-Diaz, MJ; Martin, J, 2007) |
| "Azathioprine treatment was associated with increased CIMT." | 1.35 | Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. ( Ardoin, SP; Barnhart, HX; Bowyer, SL; Brunner, HI; Eberhard, A; Evans, GW; Higgins, GC; Ilowite, NT; Jung, L; Kimura, Y; Klein-Gitelman, M; Levy, DM; McCurdy, D; Mieszkalski, KL; Punaro, L; Reed, A; Sandborg, C; Schanberg, LE; Sherry, DD; Silver, R; Silverman, E; Singer, NG; Soep, JB; von Scheven, E; Wagner-Weiner, L; Wallace, C; Yow, E, 2009) |
| "Lipid abnormalities in patients with systemic lupus erythematosus (SLE) are common and are likely to be one of the causes of premature atherosclerosis in these patients." | 1.34 | Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus. ( Beyene, J; Feldman, B; McCrindle, B; Sarkissian, T; Silverman, ED, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Shimizu, N | 1 |
| Ngayama, D | 1 |
| Watanabe, Y | 1 |
| Yamaguchi, T | 1 |
| Nakamura, S | 1 |
| Ohira, M | 1 |
| Saiki, A | 1 |
| Onda, H | 1 |
| Yamaoka, S | 1 |
| Abe, K | 1 |
| Nakaseko, C | 1 |
| Tatsuno, I | 1 |
| Rueda-Gotor, J | 1 |
| Ferraz-Amaro, I | 1 |
| Genre, F | 1 |
| González-Mazón, I | 1 |
| Corrales, A | 1 |
| Calvo-Rio, V | 1 |
| Portilla, V | 1 |
| Llorca, J | 2 |
| Expósito, R | 1 |
| Hernández-Hernández, V | 1 |
| Quevedo-Abeledo, JC | 1 |
| Rodríguez-Lozano, C | 1 |
| Lopez-Medina, C | 1 |
| Ladehesa-Pineda, ML | 1 |
| Castañeda, S | 1 |
| Vicente, EF | 1 |
| Fernández-Carballido, C | 1 |
| Martínez-Vidal, MP | 1 |
| Castro-Corredor, D | 1 |
| Anino-Fernández, J | 1 |
| Peiteado, D | 1 |
| Plasencia-Rodríguez, C | 1 |
| García-Vivar, ML | 1 |
| Galíndez-Agirregoikoa, E | 1 |
| Montes-Perez, E | 1 |
| Fernández-Díaz, C | 1 |
| Blanco, R | 1 |
| González-Gay, MÁ | 2 |
| Karpouzas, GA | 1 |
| Rezaeian, P | 1 |
| Ormseth, SR | 1 |
| Hollan, I | 1 |
| Budoff, MJ | 1 |
| Skrzypczyk, P | 1 |
| Kuźma-Mroczkowska, E | 1 |
| Kułagowska, J | 1 |
| Brzewski, M | 1 |
| Okarska-Napierała, M | 1 |
| Pańczyk-Tomaszewska, M | 1 |
| van der Matten, B | 1 |
| Zandbergen, AA | 1 |
| Dees, A | 1 |
| Schanberg, LE | 1 |
| Sandborg, C | 1 |
| Barnhart, HX | 1 |
| Ardoin, SP | 1 |
| Yow, E | 1 |
| Evans, GW | 1 |
| Mieszkalski, KL | 1 |
| Ilowite, NT | 1 |
| Eberhard, A | 1 |
| Levy, DM | 1 |
| Kimura, Y | 1 |
| von Scheven, E | 1 |
| Silverman, E | 1 |
| Bowyer, SL | 1 |
| Punaro, L | 1 |
| Singer, NG | 1 |
| Sherry, DD | 1 |
| McCurdy, D | 1 |
| Klein-Gitelman, M | 1 |
| Wallace, C | 1 |
| Silver, R | 1 |
| Wagner-Weiner, L | 1 |
| Higgins, GC | 1 |
| Brunner, HI | 1 |
| Jung, L | 1 |
| Soep, JB | 1 |
| Reed, A | 1 |
| Petri, M | 2 |
| Defuentes, G | 1 |
| Lecoules, S | 1 |
| Vedrine, L | 1 |
| Coutant, G | 1 |
| Baranger, B | 1 |
| Algayres, JP | 1 |
| Kiani, AN | 1 |
| Fishman, EK | 1 |
| Sarkissian, T | 1 |
| Beyene, J | 1 |
| Feldman, B | 1 |
| McCrindle, B | 1 |
| Silverman, ED | 1 |
| Ribichini, F | 1 |
| Joner, M | 1 |
| Ferrero, V | 1 |
| Finn, AV | 1 |
| Crimins, J | 1 |
| Nakazawa, G | 1 |
| Acampado, E | 1 |
| Kolodgie, FD | 1 |
| Vassanelli, C | 1 |
| Virmani, R | 1 |
| Genís, BB | 1 |
| Granada, ML | 1 |
| Alonso, N | 1 |
| Lauzurica, R | 1 |
| Jiménez, JA | 1 |
| Barluenga, E | 1 |
| Homs, M | 1 |
| Pastor, MC | 1 |
| Salinas, I | 1 |
| Quintero, JC | 1 |
| Sanmartí, A | 1 |
| Romero, R | 1 |
| Gonzalez-Juanatey, C | 1 |
| Lopez-Diaz, MJ | 1 |
| Martin, J | 1 |
| Telles, RW | 1 |
| Lanna, CC | 1 |
| Ferreira, GA | 1 |
| Souza, AJ | 1 |
| Navarro, TP | 1 |
| Ribeiro, AL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Test the Safety and Efficacy of Lipitor (Atorvastatin) in Reducing the Progression of Carotid IMT in Early Childhood SLE[NCT00065806] | Phase 3 | 221 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| Assessment of Lipid Profile in Juvenile Systemic Lupus Erythematosus[NCT06151990] | 102 participants (Anticipated) | Observational | 2023-12-31 | Recruiting | |||
| Clinical and Angiographic Outcome of Patients Treated With Bare Metal Stent (BMS) Implantation Compared With Drug Eluting Stents or BMS Plus Systemic Prednisone Therapy. A Randomized, Multicentre Study.[NCT00369356] | Phase 2/Phase 3 | 375 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mg/dl (Mean) |
|---|---|
| 1 Atorvastatin | -0.43 |
| 2 Placebo | 0.89 |
(NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | μmoles/liter (Mean) |
|---|---|
| 1 Atorvastatin | 1.84 |
| 2 Placebo | 1.76 |
(NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mg/dl (Mean) |
|---|---|
| 1 Atorvastatin | -27.63 |
| 2 Placebo | -1.48 |
(NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mg/dl (Mean) |
|---|---|
| 1 Atorvastatin | 2.00 |
| 2 Placebo | 6.34 |
For each side and wall of the bifurcation arterial segment, the maximum CIMT over the 4 angles of interrogation was selected to produce 4 summary variables (right bifurcation near wall max, right bifurcation far wall max, left bifurcation near wall max and left bifurcation far wall max). These summary variables were then averaged to estimate a single mean-max bifurcation CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mm (Mean) |
|---|---|
| 1 Atorvastatin | 0.0033 |
| 2 Placebo | 0.0072 |
For each side, segment and wall, the maximum CIMT over the 4 angles of interrogation was selected to produce 12 summary variables (right common near wall max, right common far wall max, right bifurcation near wall max, right bifurcation far wall max, right internal near wall max, right internal far wall max, left common near wall max, left common far wall max, left bifurcation near wall max, left bifurcation far wall max, left internal near wall max and left internal far wall max). These 12 summary variables were then averaged to estimate a single mean-max CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mm (Mean) |
|---|---|
| 1 Atorvastatin | 0.0037 |
| 2 Placebo | 0.0064 |
For each side and wall of the common carotid arterial segment, the maximum CIMT over the 4 angles of interrogation was selected to produce 4 summary variables (right common near wall max, right common far wall max, left common near wall max and left common far wall max). These summary variables were then averaged to estimate a single mean-max common CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mm (Mean) |
|---|---|
| 1 Atorvastatin | 0.0006 |
| 2 Placebo | 0.0008 |
For the far wall measurements for each side and segment, the maximum CIMT over the 4 angles of interrogation was selected to produce 6 summary variables (right common far wall max, right bifurcation far wall max, right internal far wall max, left common far wall max, left bifurcation far wall max, and left internal far wall max). These 6 summary variables were then averaged to estimate a single mean-max far wall CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mm (Mean) |
|---|---|
| 1 Atorvastatin | 0.0045 |
| 2 Placebo | 0.0082 |
For each side and wall of the internal carotid arterial segment, the maximum CIMT over the 4 angles of interrogation was selected to produce 4 summary variables (right internal near wall max, right internal far wall max, left internal near wall max and left internal far wall max). These summary variables were then averaged to estimate a single mean-max internal CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mm (Mean) |
|---|---|
| 1 Atorvastatin | 0.0090 |
| 2 Placebo | 0.0144 |
For the near wall measurements for each side and segment, the maximum CIMT over the 4 angles of interrogation was selected to produce 6 summary variables (right common near wall max, right bifurcation near wall max, right internal near wall max, left common near wall max, left bifurcation near wall max, and left internal near wall max). These 6 summary variables were then averaged to estimate a single mean-max near wall CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mm (Mean) |
|---|---|
| 1 Atorvastatin | 0.0024 |
| 2 Placebo | 0.0038 |
For the bifurcation arterial segment, mean CIMT values were averaged across angles by side and wall to produce 4 summary variables (right bifurcation near wall mean, right bifurcation far wall mean, left bifurcation near wall mean and left bifurcation far wall mean). These summary variables were then averaged to estimate a single mean-mean bifurcation CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mm (Mean) |
|---|---|
| 1 Atorvastatin | 0.0030 |
| 2 Placebo | 0.0055 |
For each side, segment and wall, mean CIMT values were averaged over the 4 angles of interrogation to produce 12 summary variables (right common near wall mean, right common far wall mean, right bifurcation near wall mean, right bifurcation far wall mean, right internal near wall mean, right internal far wall mean, left common near wall mean, left common far wall mean, left bifurcation near wall mean, left bifurcation far wall mean, left internal near wall mean and left internal far wall mean). These 12 summary variables were then averaged to estimate a single mean-mean CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mm (Mean) |
|---|---|
| 1 Atorvastatin | 0.0033 |
| 2 Placebo | 0.0049 |
For the common carotid arterial segment, mean CIMT values were averaged across angles by side and wall to produce 4 summary variables (right common near wall mean, right common far wall mean, left common near wall mean and left common far wall mean). These summary variables were then averaged to estimate a single mean-mean common CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mm (Mean) |
|---|---|
| 1 Atorvastatin | 0.0010 |
| 2 Placebo | 0.0024 |
For the far wall measurements for each side and segment, mean CIMT values were averaged over the 4 angles of interrogation to produce 6 summary variables (right common far wall mean, right bifurcation far wall mean, right internal far wall mean, left common far wall mean, left bifurcation far wall mean and left internal far wall mean). These 6 summary variables were then averaged to estimate a single mean-mean far wall CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mm (Mean) |
|---|---|
| 1 Atorvastatin | 0.0042 |
| 2 Placebo | 0.0064 |
For the internal carotid arterial segment, mean CIMT values were averaged across angles by side and wall to produce 4 summary variables (right internal near wall mean, right internal far wall mean, left internal near wall mean and left internal far wall mean). These summary variables were then averaged to estimate a single mean-mean internal CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mm (Mean) |
|---|---|
| 1 Atorvastatin | 0.0067 |
| 2 Placebo | 0.0082 |
For the near wall measurements for each side and segment, mean CIMT values were averaged over the 4 angles of interrogation to produce 6 summary variables (right common near wall mean, right bifurcation near wall mean, right internal near wall mean, left common near wall mean, left bifurcation wall mean and left internal far wall mean). These 6 summary variables were then averaged to estimate a single mean-mean far wall CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mm (Mean) |
|---|---|
| 1 Atorvastatin | 0.0022 |
| 2 Placebo | 0.0028 |
(NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | natural log of mg/L (Mean) |
|---|---|
| 1 Atorvastatin | -0.13 |
| 2 Placebo | 0.27 |
(NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mg/dl (Mean) |
|---|---|
| 1 Atorvastatin | -30.30 |
| 2 Placebo | -0.72 |
(NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mg/dl (Mean) |
|---|---|
| 1 Atorvastatin | -11.04 |
| 2 Placebo | -5.62 |
1 trial available for prednisone and Atherogenesis
| Article | Year |
|---|---|
Aortic valve calcification in systemic lupus erythematosus.
Topics: Adult; Aortic Valve Stenosis; Atherosclerosis; Calcinosis; Female; Glucocorticoids; Humans; Immunosu | 2006 |
13 other studies available for prednisone and Atherogenesis
| Article | Year |
|---|---|
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy increases carotid intima-media thickness and plaque score with von Willebrand factor activity elevation in patients with malignant lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Atherosclerosis; Carotid Intima-Media Thickness; Cyc | 2022 |
Factors associated with atherosclerosis in radiographic and non-radiographic axial spondyloarthritis. A multicenter study on 838 patients.
Topics: Antirheumatic Agents; Atherosclerosis; Axial Spondyloarthritis; Carotid Intima-Media Thickness; Cros | 2022 |
Epicardial Adipose Tissue Volume As a Marker of Subclinical Coronary Atherosclerosis in Rheumatoid Arthritis.
Topics: Adipose Tissue; Arthritis, Rheumatoid; Atherosclerosis; Biomarkers; C-Reactive Protein; Case-Control | 2021 |
Carotid intima-media thickness in children with idiopathic nephrotic syndrome: A single center cross-sectional study
.
Topics: Adolescent; Anti-Inflammatory Agents; Arterial Pressure; Atherosclerosis; Body Mass Index; Carotid A | 2019 |
Bilateral axillary arterial obstruction.
Topics: Aged; Arterial Occlusive Diseases; Atherosclerosis; Axillary Artery; Diagnosis, Differential; Female | 2014 |
Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort.
Topics: Adolescent; Atherosclerosis; Azathioprine; Body Mass Index; Carotid Artery, Common; Child; Creatinin | 2009 |
Clinical research in systemic lupus erythematosus: immediate relevance to clinical practice.
Topics: Adult; Atherosclerosis; Biomedical Research; Female; Humans; Lupus Erythematosus, Systemic; Lupus Ne | 2011 |
[Accelerated atheroma with prednisone and clopidogrel].
Topics: Aged; Atherosclerosis; Carotid Stenosis; Clopidogrel; Endarterectomy; Giant Cell Arteritis; Glucocor | 2006 |
Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus.
Topics: Adolescent; Adult; Atherosclerosis; Child; Child, Preschool; Cohort Studies; Disease Progression; Do | 2007 |
Effects of oral prednisone after stenting in a rabbit model of established atherosclerosis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Aorta; Atherosclerosis; Cell Proliferation; | 2007 |
Ghrelin, glucose homeostasis, and carotid intima media thickness in kidney transplantation.
Topics: Atherosclerosis; Blood Glucose; Carotid Arteries; Cross-Sectional Studies; Female; Ghrelin; Glucocor | 2007 |
Atherosclerosis in patients with biopsy-proven giant cell arteritis.
Topics: Aged; Atherosclerosis; Biopsy; Carotid Arteries; Case-Control Studies; Female; Giant Cell Arteritis; | 2007 |
Carotid atherosclerotic alterations in systemic lupus erythematosus patients treated at a Brazilian university setting.
Topics: Adult; Atherosclerosis; Brazil; Carotid Artery Diseases; Carotid Stenosis; Cholesterol, LDL; Cross-S | 2008 |